ClinicalTrials.gg
CompletedNCT04987190CDAABGUpdated Aug 6, 2021

Progression of Grafted Bone Density in Cleft Alveolus

An observational study in Cleft Lip and Palate, sponsored by Chang Gung Memorial Hospital. Completed at 1 site in Taiwan. Open to participants aged 8 Years to 10 Years. Per ClinicalTrials.gov, last updated 2021-08-06.

Sponsored by Chang Gung Memorial Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
40
Ages
8 Years to 10 Years
Sex
All
01

Study summary

The patients with unilateral and bilateral cleft lip and palate received alveolar bone graft surgery. Two time points of cone beam CT were taken for all the patients: post-operative 6 months, and post-operative 2 years. All the CT images were reviewed for the analysis of grafted bone density.

Read the detailed description

Patient Information and Data Collection Patients who had nonsyndromic unilateral or bilateral cleft lip and alveolus with or without cleft palate and received ABG at our center between 2016 and 2018 were enrolled. All patients underwent at least 2 CBCT scans after operation. Postoperative image acquisition was performed at two time points, namely 6 months (T1) and 2 years (T2) after ABG. The ABG procedures for all patients were performed by the same senior surgeon per the protocol of our center, which comprises an iliac cancellous bone graft and the sealing of the Scarpa fascia to the defect before the bone graft is packed.2,12 Patient who had syndromic cleft alveolus, who underwent two-stage ABG (performed for bilateral cases), or who exhibited failed grafted tissue were excluded. In total, 40 patients were enrolled in the present study. The demographic and clinical variables for ABG were retrospectively collected through a review of medical charts. All CBCT images were obtained using an i-CAT CBCT scanner (Imaging Sciences International, Hatfield, PA, USA); the parameters for the images are as follows: 120 kVp, voxel size of 0.4 × 0.4 × 0.4 mm3, 40-s scan time, and 22 × 16-cm field of view.

BMD Measurement The Picture Archiving and Communication System (PACS) was applied for image analysis. In addition, areas of interest were checked in the axial view slice by slice to locate the grafted tissue. Three methods (A, B, and C), which differed by the size of the selected area, were designed to measure Hounsfield units (HU). For all methods, we first identified the most superior and inferior planes transecting the grafted tissue. Subsequently, the middle plane of the grafted tissue was identified. For the selected plane, the distance between two teeth had to be larger than 2.5 mm in diameter; this was required for all three methods. On each plane, the selected circular area is defined as being located at the midpoint of the line between the centers of the two adjacent teeth. The HU of the selected area could be obtained using PACS.

For Method A, the circular zone located 1 mm from the adjacent teeth was selected. For Method B, the largest circular zone that exactly transected the two adjacent teeth or was tangent to the surrounding cortical bone was selected. For Method C, a circle was drawn with a diameter of 2 mm. Furthermore, an area of 2 × 0.5 mm2 in the pogonion was selected to obtain its HU at T1 and T2; this was the reference for calibration (Figure, Supplemental Digital Content 1). HU was the reference for BMD13 and represented the average density of the three planes. Calibrated BMD (BMDc, %) was defined using the following formula:

〖BMD〗_c (%)=〖HU〗_(selected zone)/〖HU〗_pogonion ×100.

Density enhancement rate (%) was calculated using the following formula:

Density enhancing rate (%)= (〖BMD〗_cT2-〖BMD〗_cT1)/〖BMD〗_cT1 ×100, where BMDcT2 is BMDc measured at T2, and BMDcT1 is the BMDc at T1. All the BMD and pogonion density data were measured by one examiner and repeated twice on different dates that were separated by a 3-month interval; the second round of measurements was conducted without reference to the first-round measurements. The average of the six sets of data (two measurements for each of the three planes) was used for the final statistical analysis.

Statistical Analysis In the descriptive analysis, continuous variables were summarized by means ± standard deviations. All variables were examined for normal distribution using the Shapiro-Wilk test. Student's t-test was performed to compare the means of continuous variables with normal distribution, and a chi-squared test or Fisher's exact test was used for categorical data. Furthermore, we performed analysis of variance with repeated measures to compare the differences between the three methods with respect to BMDc measurements and density enhancement rates in normally distributed data; for data that were not normally distributed, Friedman test was used. To compare the differences in BMDc at T1 and T2, we performed a paired t-test and a Wilcoxon signed-rank test for bilateral cleft due to small sample size. Bland-Altman plots were used to evaluate the agreement of each method. Intrarater reliability for the three methods was calculated using intraclass correlation coefficients (ICCs). All statistical tests were two-tailed, and a p value less than 0.05 was considered statistically significant. All data were analyzed using SPSS 24.0 (SPSS, Chicago, IL, USA).

02

Conditions studied

  • Cleft Lip and Palate

Browse trials for

Keywords

  • alveolar bone grafting
  • alveolar cleft
  • bone mineral density
  • density enhancement rate
  • cone beam computed tomography (CBCT)
03

In context

Cleft Lip

167 studies on the registry are indexed under Cleft Lip; 53 are open to participants now.

This study's enrollment of 40 is below the median of 100 across 47 observational studies indexed under Cleft Lip.

Browse Cleft Lip studies →

Lead sponsor

Chang Gung Memorial Hospital is the lead sponsor of 1,091 studies on the registry; 237 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

In total, 40 patients, who had an average age of 9.45 ± 1.61 years when they received ABG, were enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who had nonsyndromic unilateral or bilateral cleft lip and alveolus with or without cleft palate
  • Patients received alveolar bone graft at their 9 years of age
  • Patients received twice CBCT after the surgery

Exclusion criteria

Exclusion Criteria:

  • Patient had syndromic cleft alveolus
  • Patient underwent two-stage ABG (performed for bilateral cases)
  • Patient exhibited failed grafted tissue
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
40 participants (actual)
Patient registry
No

Groups and cohorts

  • all cleft patients divided into unilateral and bilateral groups

    One group of cleft patients received the alveolar bone graft surgery

    Procedure: alveolar bone graft

Interventions

  • Procedurealveolar bone graft

    alveolar bone graft with Scarpa fascia done when patients were at 9 year of age

06

What researchers measure

Primary outcomes

  1. mean calibrated bone mineral density (BMD/pogonion density, BMDc)

    BMD presented from CBCT

    Time frame: 1st BMD at post-operative 6 months

  2. mean calibrated bone mineral density (BMD/pogonion density, BMDc)

    BMD presented from CBCT

    Time frame: 2nd BMD at post-operative 2 years

07

Study locations

1 site
  • Chang Gung Memorial Hospital
    Taoyuan, Taiwan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Jun 2021, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2021
First posted
Aug 3, 2021
StartActual
Jan 25, 2021
Primary completionActual
Jun 2, 2021
CompletionActual
Jul 4, 2021
Last update
Aug 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04987190
Responsible party
Pangyunchou (Craniofacial Research Center, Chang Gung Memorial Hospital) — Principal investigator
First posted
Aug 3, 2021
Start date
Jan 25, 2021
Primary completion
Jun 2, 2021
Completion
Jul 4, 2021
Last update
Aug 6, 2021

Study contacts

Pangyun Chou, MD
principal investigator · Chang Gung Memorial Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion